Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active
 compound in asthmatic patients.
Inclusion Criteria:

 -  Men and women. Women must be surgically sterilized/postmenopausal or use double
 barrier method contraception

 -  6 months history of asthma according to ATS definition

 -  Prescribed daily dose of ICS and LABA for at least 3 months prior to Visit 2

 -  Pre-bronchodilator FEV1 of 40 to 85 % of predicted normal

 -  A total ACQ5 score of 1.5 or more

 Exclusion Criteria:

 -  Respiratory infection significantly affecting the asthma

 -  Any significant disease and disorder that may put the patient at risk or influence
 study results

 -  Any clinically relevant abnormal findings

 -  A smoking history of more than 10 pack years

 -  Intake of oral, rectal or parenteral glucocorticosteroids